Effect of Symbicort nasal exhalation for eosinophilic rhinosinusitis with bronchial asthma

Effect of Symbicort nasal exhalation for eosinophilic rhinosinusitis with bronchial asthma - Nasal exhalation of Symbicort for ECRS with asthma

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000028765

Enrollment

Registered

2017-08-23

Start date

2017-09-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

eosinophilic rhinosinusitis bronchial asthma

Interventions

nasal exhalation of budesonide/formoterol dry powder after inhalation with flow rate of 60L/min. 4puff twice a day for three month oral exhalation of budesonide/formoterol dry powder after inhalati

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: moderate to severe bronchial asthma with eosinophilic rhinosinusitis (JESREC clinical score is 11 or more). Who can stop prohibited medication for during the given period.

Exclusion criteria

Exclusion criteria: 1) intranasal steroid, systemic corticosteroid, depo-triamcinolone, Shinni-Seihai Tou, mepolizumab are prescribed. 2)Systemic steroid prescribed twice or more within one month. 3)Omalizumab or LTRA is begun within 6 month. 4)Who has a complication considered to affect the evaluation of this study.

Design outcomes

Primary

Measure	Time frame
Evaluation of Lund-Mackay CT score three month after the intervention	—

Secondary

Measure	Time frame
%FEV1.0, %MMEF, percentage of peripheral blood eosinophil, Asthma Control Test (ACT), symptom scores of disturbance of smell and nasal obstruction	—

Countries

Japan

Contacts

Public ContactHirotaka Yasuba

Mitsubishi Kyoto Hospital Allergy and pulmonary medicine

hyacchan@ga2.so-net.ne.jp075-381-2111

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026